Zevra Therapeutics, Inc. (ZVRA)
9.99
-0.19
(-1.87%)
USD |
NASDAQ |
Oct 02, 16:00
9.975
-0.02
(-0.15%)
After-Hours: 20:00
Zevra Therapeutics Price to Book Value : 2.724 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.724 |
| October 01, 2026 | 2.776 |
| September 30, 2026 | 2.991 |
| September 29, 2026 | 3.092 |
| September 28, 2026 | 3.081 |
| September 25, 2026 | 3.01 |
| September 24, 2026 | 3.07 |
| September 23, 2026 | 3.086 |
| September 22, 2026 | 3.157 |
| September 21, 2026 | 3.182 |
| September 18, 2026 | 3.165 |
| September 17, 2026 | 3.228 |
| September 16, 2026 | 3.217 |
| September 15, 2026 | 3.176 |
| September 14, 2026 | 3.285 |
| September 11, 2026 | 3.274 |
| September 10, 2026 | 3.288 |
| September 09, 2026 | 3.283 |
| September 08, 2026 | 3.456 |
| September 04, 2026 | 3.381 |
| September 03, 2026 | 3.419 |
| September 02, 2026 | 3.354 |
| September 01, 2026 | 3.288 |
| August 31, 2026 | 3.201 |
| August 28, 2026 | 3.153 |
| Date | Value |
|---|---|
| August 27, 2026 | 3.231 |
| August 26, 2026 | 3.201 |
| August 25, 2026 | 3.283 |
| August 24, 2026 | 3.176 |
| August 21, 2026 | 3.236 |
| August 20, 2026 | 3.242 |
| August 19, 2026 | 3.307 |
| August 18, 2026 | 3.154 |
| August 17, 2026 | 3.144 |
| August 14, 2026 | 3.086 |
| August 13, 2026 | 3.048 |
| August 12, 2026 | 3.119 |
| August 11, 2026 | 3.092 |
| August 10, 2026 | 3.13 |
| August 07, 2026 | 3.152 |
| August 06, 2026 | 3.239 |
| August 05, 2026 | 2.871 |
| August 04, 2026 | 2.868 |
| August 03, 2026 | 2.742 |
| July 31, 2026 | 2.593 |
| July 30, 2026 | 2.628 |
| July 29, 2026 | 2.666 |
| July 28, 2026 | 2.653 |
| July 27, 2026 | 2.647 |
| July 24, 2026 | 2.597 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Innoviva, Inc. | 1.207 |
| Johnson & Johnson | 7.256 |
| Ligand Pharmaceuticals, Inc. | 6.238 |
| Collegium Pharmaceutical, Inc. | 2.294 |
| Xeris Biopharma Holdings, Inc. | -- |
Price to Book Value Related Metrics
| PE Ratio | 10.78 |
| PS Ratio | 4.361 |
| Price to Free Cash Flow | 18.19 |
| Price | 9.99 |
| Earnings Yield | 9.28% |
| Market Cap | 592.83M |
| Operating PE Ratio | 15.19 |
| Normalized PE Ratio | 8.806 |